James Dahlman is an Assistant Professor in the Department of Biomedical Engineering at Georgia Tech and Emory Medical School. He studied RNA design and gene editing as a post-doc with Feng Zhang at the Broad Institute, and received his PhD from MIT and Harvard Medical School, where he studied RNA delivery with Robert Langer and Daniel Anderson.
The Lab for Precision Therapies at Georgia Tech, also called the “Dahlman Lab,” works at the interface of drug delivery, nanotechnology, genomics, and gene editing. James has designed nanoparticles that have been licensed for clinical development. He has also developed targeted in vivo combination therapies; nanoparticles deliver multiple therapeutic RNAs at once, in order to manipulate several nodes on a single disease pathway. More recently, he has developed methods to barcode nanoparticles, in order to study how thousands work in vivo for the first time. More generally, James and his students use molecular biology and technology development approaches to rationally improve nanomedicines.
As a student, James won the NSF, NDSEG, NIH OxCam, Whitaker Graduate, and LSRF Fellowships, as well as the Weintraub Graduate Thesis Award. Within his first 3 years as a professor, James grew his lab to 20 people, was named a Bayer Young Investigator, a Parkinson’s Disease Foundation Young Investigator, a CMBE Young Investigator, and was named to the MIT TR35 list. James also won 5 major teaching awards in his first 2 years at Georgia Tech. At the age of 32, James has published / submitted more than 40 papers to Science, Cell, Nature Biotech, Nature Nanotech (2x), Nature Cell Biology, Science Translational Medicine, PNAS (3x), JACS (2x), Advanced Materials, and many other journals. He has also given invited talks on gene therapy and DNA barcoding over 70 times across the world.